$OWLT

Owlet (NYSE: OWLT) CFO takes bonus in stock, shares withheld for tax

Owlet, Inc. CFO Amanda Crawford received 32,032 shares of common stock as her 2025 annual incentive bonus, valued at $157,531. Concurrently, 9,242 shares were withheld to cover tax obligations related to vested restricted stock units. After these transactions, Crawford directly holds 159,820 shares of Owlet common stock, with the stock bonus viewed as a routine compensation event rather than a discretionary market transaction.

Original reporting
Published Apr 8, 2026, 4:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 8, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$OWLT
Neutral
medium confidence
Mentioned
$OWLT
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$OWLTNeutralLow
01

Why it matters

The insider activity suggests management's confidence but is standard practice; unlikely to cause significant market movement.

02

Market read

The news is highly relevant to Owlet's stock but has limited broader market impact.

03

What to watch

Potential upcoming company developments or earnings reports could have a more significant impact than insider stock movements.

Timing: short-term

Background

Owlet's CFO received stock bonuses as part of routine compensation for the fiscal year 2025, with shares withheld for tax obligations.

Company-level read

Ticker impact

$OWLTNeutralMedium confidence
Context

The news pertains directly to Owlet's insider trading activity, indicating internal stock movements.

Expected impact

Minimal immediate impact; potential slight upward movement over the medium term if insider confidence translates into positive market perception.

Evidence & confidence

While insider stock awards can signal confidence, they are routine compensation events and do not necessarily predict short-term price movements.

Market effects

Limited sector impact; Owlet operates in the healthcare technology sector, which is not directly affected by individual insider transactions.

Negligible regional effects; the news is company-specific.

Negligible; the event does not influence global markets.

Counterpoint

Insider stock awards may be routine and not indicative of future performance; overreliance on such signals can be misleading.

Key entities

  • Amanda Crawford

    Chief Financial Officer of Owlet, Inc.

  • Owlet, Inc.

    A healthcare technology company specializing in baby monitoring devices.

Related articles

$SMCIHighAI 8/10

Super Micro jumps premarket on outlook boost, H&R Block surges

U.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.

$OWLTMed

Owlet, Inc. (OWLT): Results of Operations and Financial Condition

Owlet, Inc. (OWLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991q226earningspressrel.htm EX-99.1 Document Owlet Announces Second Quarter 2026 Financial Results LEHI, Utah, August 11, 2026 - Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today reports financial results for the secon

$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.